DRG therapy is a new, non-opioid treatment option providing effective relief so you can focus on your life, not on your pain.
If you are experiencing pain in your knee, hip, groin or foot† following surgery, trauma, injury, amputation or other pre-existing condition, you may have a type of nerve pain called causalgia. Nerve pain is difficult to treat and many patients have tried multiple options, including medication, to try and find relief. Today, there’s a better answer.
Abbott developed DRG therapy specifically for people like you. A long-term clinical study shows that DRG therapy provides1:
Living with chronic pain affects everything you do. Research on DRG therapy shows that patients report improvements on many quality of life measures, from physical activity to overall mood1.
Finding an expert trained in DRG therapy is easy. DRG therapy is covered by most medical insurance plans, so there’s no reason to wait.
Use our clinic locator to find an expert DRG physician near you. You’re just a few steps away from relieving the burden of pain.
Brief Summary: Prior to using these devices, please review the User’s Guide for a listing of indications, contraindications, warnings, precautions, potential events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.
Indications for Use: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.**
Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.
Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively.
Contraindications: Patients who are unable to operate the system, who are poor risks, or who have failed to receive effective pain relief during trial stimulation.
Warnings/Precautions: Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive or flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery and equipment, pediatric use, pregnancy, and case damage.
Adverse Effects: Painful stimulation, loss of pain relief, surgical risks (e.g., paralysis). User’s Guide must be reviewed for detailed disclosure.
CAUTION: FEDERAL LAW (USA) RESTRICTS THIS DEVICE TO SALE, AND USE BY OR ON THE ORDER OF A PHYSICIAN.